RHPN2 drives mesenchymal transformation in malignant glioma by triggering RhoA activation

Cancer Research

Volumn 73, Issue 16, 2013, Pages 5140-5150

  Danussi, Carla ^a   Akavia, Uri David ^a   Niola, Francesco ^a,c   Jovic, Andreja ^a   Lasorella, Anna ^a   Pe'Er, Dana ^a   Iavarone, Antonio ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOPHILIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASTROCYTE; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME 19; CONTROLLED STUDY; COPY NUMBER VARIATION; ENZYME ACTIVATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MESENCHYME; MOUSE; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHPN2 GENE; TUMOR INVASION;

EID: 84882654308     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1168-T     Document Type: Article

References (34)

1. Schonsteiner SS, Bommer M, Haenle MM, Klaus B, Scheuerle A, Schmid M, et al. Rare phenomenon: liver metastases from glioblastoma multiforme. J Clin Oncol 2011;29:e668-71.
2. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003;21:1624-36.
3. Goldberg L, Kloog Y. A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer Res 2006;66:11709-17.
4. Feng H, Hu B, Liu KW, Li Y, Lu X, Cheng T, et al. Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRalpha-stimulated glioma tumorigenesis in mice and humans. J Clin Invest 2011;121:4670-84.
5. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359:492-507.
6. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73.
7. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
8. Sturm D, Witt H, Hovestadt V, Khuong-Quang D-A, Jones DTW, Konermann C, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012;22:425-37.
9. Huse JT, Phillips HS, Brennan CW. Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia 2011;59:1190-9.
10. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004;64:6503-10.
11. PaughBS,QuC,Jones C, LiuZ,Adamowicz-BriceM,ZhangJ, et al. Integratedmoleculargeneticprofilingofpediatrichigh- gradegliomasreveals key differences with the adult disease. J Clin Oncol 2010;28:3061-8.
12. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010;463:318-25.
13. Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 2011;25: 2594-609.
14. Parker MA, Anderson JK, Corliss DA, Abraria VE, Sidman RL, Park KI, et al. Expression profile of an operationally-defined neural stem cell clone. Exp Neurol 2005;194:320-32.
15. Zhao X, Heng JI, Guardavaccaro D, Jiang R, Pagano M, Guillemot F, et al. The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein. Nat Cell Biol 2008;10:643-53.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8.
17. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008;24:1547-8.
18. Burris HA III, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)- positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29:398-405.
19. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
20. Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, Causton HC, et al. An integrated approach to uncover drivers of cancer. Cell 2010;143:1005-17.
21. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
22. Adler AS, Lin M, Horlings H, Nuyten DS, van de Vijver MJ, Chang HY. Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet 2006;38:421-30.
23. Sanchez-Garcia F, Akavia UD, Mozes E, Pe'er D. JISTIC: identification of significant targets in cancer. BMC Bioinformatics 2010;11:189.
24. Peck JW, Oberst M, Bouker KB, Bowden E, Burbelo PD. The RhoAbinding protein, rhophilin-2, regulates actin cytoskeleton organization. J Biol Chem 2002;277:43924-32.
25. Schaller MD. Paxillin: a focal adhesion-associated adaptor protein. Oncogene 2001;20:6459-72.
26. Toshima J, Toshima JY, Amano T, Yang N, Narumiya S, Mizuno K. Cofilin phosphorylation by protein kinase testicular protein kinase 1 and its role in integrin-mediated actin reorganization and focal adhesion formation. Mol Biol Cell 2001;12:1131-45.
27. Jornsten R, Abenius T, Kling T, Schmidt L, Johansson E, Nordling TE, et al. Network modeling of the transcriptional effects of copy number aberrations in glioblastoma. Mol Syst Biol 2011;7:486.
28. Chen Y, Sheng R, Kallberg M, Silkov A, Tun MP, Bhardwaj N, et al. Genome-wide functional annotation of dual-specificity protein- and lipid-binding modules that regulate protein interactions. Mol Cell 2012;46:226-37.
29. Steuve S, Devosse T, Lauwers E, Vanderwinden JM, Andre B, Courtoy PJ, et al. Rhophilin-2 is targeted to late-endosomal structures of the vesicular machinery in the presence of activated RhoB. Exp Cell Res 2006;312:3981-9.
30. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 2008;135:852-64.
31. Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett 2008;582:2093-101.
32. Khalil BD, El-Sibai M. Rho GTPases in primary brain tumor malignancy and invasion. J Neurooncol 2012;108:333-9.
33. Manning TJ Jr, Parker JC, Sontheimer H. Role of lysophosphatidic acid and rho in glioma cell motility. Cell Motil Cytoskeleton 2000;45: 185-99.
34. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002;2:133-42.